Evidence map›Paper›PMID 18591260›Full record

ReviewEndocrine reviews2008

Clinical, agricultural, and evolutionary biology of myostatin: a comparative review.

Buel D Rodgers, Dilip K Garikipati

Open access · bronzeAbstract readComparative StudyReview
In one paragraph

Review in Endocrine reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 234 citations in OpenAlex.

  1. Trial
  2. Loss of Intestinal MSTN Promotes GLP-1 Secretion Through SGLT1 Palmitoylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Skeletal Muscle as Endocrine Organ.Advances in experimental medicine and biology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Effects of functional training with blood occlusion on the irisin, follistatin, and myostatin myokines in elderly men.European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity · 2022
    Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Buel D RodgersDepartment of Animal Sciences, 124 ASLB, Washington State University, Pullman, Washington 99164, USA. danrodgers@wsu.edu
Dilip K Garikipati
University of Washington · USWashington State University · US

Funding

Nuclear Actions of IGFBP-3 in Developing Muscle CellsR03AR051917 · NIAMS · WASHINGTON STATE UNIVERSITY · PI RODGERS, BUEL DANTESE · 2007 to 2009
$220k
NIAMS NIH HHS 1R03AR051917NIAMS NIH HHS R03 AR051917
6 · The paper itself

Abstract

The discovery of myostatin and our introduction to the "Mighty Mouse" over a decade ago spurred both basic and applied research and impacted popular culture as well. The myostatin-null genotype produces "double muscling" in mice and livestock and was recently described in a child. The field's rapid growth is by no means surprising considering the potential benefits of enhancing muscle growth in clinical and agricultural settings. Indeed, several recent studies suggest that blocking myostatin's inhibitory effects could improve the clinical treatment of several muscle growth disorders, whereas comparative studies suggest that these actions are at least partly conserved. Thus, neutralizing myostatin's effects could also have agricultural significance. Extrapolating between studies that use different vertebrate models, particularly fish and mammals, is somewhat confusing because whole genome duplication events have resulted in the production and retention of up to four unique myostatin genes in some fish species. Such comparisons, however, suggest that myostatin's actions may not be limited to skeletal muscle per se, but may additionally influence other tissues including cardiac muscle, adipocytes, and the brain. Thus, therapeutic intervention in the clinic or on the farm must consider the potential of alternative side effects that could impact these or other tissues. In addition, the presence of multiple and actively diversifying myostatin genes in most fish species provides a unique opportunity to study adaptive molecular evolution. It may also provide insight into myostatin's nonmuscle actions as results from these and other comparative studies gain visibility in biomedical fields.

Indexed as

Adipose TissueAgricultureAnimalsBrainCattleEvolution, MolecularFishesHeartHumansMiceMuscular DiseasesMyostatinSheepTransforming Growth Factor betaMSTN protein, humanMstn protein, mouseMyostatinTransforming Growth Factor beta

Identifiers

PMID18591260
PMCPMC2528853
OpenAlexW2104717998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.